Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, novembre 17
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
BioHarvest Sciences Inc
BHST
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.38
-0.13
-8.31%
In chiusura: Nov 16, 4:00 PM EST
$1.38
N/A
Post-mercato: 4:11 PM EST
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Confronta
Rapporto azionario
Utili:
I risultati di Q3 2026 sono stati pubblicati in data gio nov 12th, prima dell'apertura del mercato
Conference call:
La conference call più recente è iniziata alle 8:00 AM, 5 giorni fa
Clicca per vedere il webcast
BioHarvest Sciences Financials
BioHarvest Sciences (BHST) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Conference call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $37.000M-$40.000M to $32.000M-$33.500M vs $37.461M Est
BioHarvest Sciences (NASDAQ:BHST) lowers FY2026 sales outlook from $37.000 million-$40.000 million to $32.000 million-$33.500 million vs $37.461 million estimate.
Benzinga Newsdesk
PRO
BioHarvest Sciences Inc. - Common Stock Q3 EPS $(0.15) Misses $(0.14) Estimate, Sales $7.867M Miss $9.371M Estimate
BioHarvest Sciences Inc. - Common Stock (NASDAQ:BHST) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 7.14 percent decrease over losses of
Benzinga Newsdesk
PRO
Conference Call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $42.000M-$48.000M to $37.000M-$40.000M vs $42.914M Est
BioHarvest Sciences (NASDAQ:BHST) lowers FY2026 sales outlook from $42.000 million-$48.000 million to $37.000 million-$40.000 million vs $42.914 million estimate.
Benzinga Newsdesk
PRO
BioHarvest Sciences Revises FY26 CDMO Revenue Guidance to $4M-$5M from $4M-$6M; VINIA D2C Revenue Guidance to $33M-$35M from $38M-$42M
BioHarvest Sciences (NASDAQ:BHST) stated that full-year 2026 revenue guidance for its CDMO business has been narrowed to $4 million-$5 million, from $4 million-$6 million previously, while revenue guidance for the VINIA
Benzinga Newsdesk
PRO
BioHarvest Sciences Inc. - Common Stock Q2 EPS $(0.17) Misses $(0.12) Estimate, Sales $8.837M Miss $9.537M Estimate
Benzinga Newsdesk
PRO
BioHarvest Sciences Affirms FY2026 Sales Guidance of $42.000M-$48.000M vs $44.721M Est
BioHarvest Sciences (NASDAQ:BHST) affirms FY2026 sales outlook from $42.000 million-$48.000 million to $42.000 million-$48.000 million vs $44.721 million estimate.
Benzinga Newsdesk